The growing incidence rate of chronic diseases is leading to the high occurrence of chronic musculoskeletal pain, which is anticipated to create an upward trend for the demand witnessed in the tapentadol market. Tapentadol is also used for the treatment of moderate to severe pain. The medicine has lower side effects, and analgesic efficacy is comparable to that of oxycodone. The medication is prescribed to adults and not to children as there is no well-controlled study reported for children. The rising occurrence of diabetes is also working in favor of the global tapentadol market.
Tapentadol is in the launch or post-launch phase in several countries across and awaiting to be commercially introduced in numerous countries. Tapentadol is a dual mode analgesic that acts as a norepinephrine reuptake inhibitor and also a mu-opioid receptor antagonist. Within few minutes of oral administration its analgesic properties come into effect. Tapentadol has been recognized as a step three analgesic on the WHO pain ladder. Tapentadol is used for the treatment of moderate to acute pain for chronic and severe musculoskeletal pain. It is available in the U.S. in extended release formulations.
Tapentadol is a newly released drug, which was approved by the U.S. Food and Drug Administration in 2011, by the Therapeutic Goods Administration of Australia in 2010 and by the Medicines and Healthcare products Regulatory Agency of the U.K. in 2011.
Request a Sample@ https://qyresearchmedical.com/sample/119075
Tapentadol is frequenty used to manage pain, which cannot be eased with other types of analgesics. Its application segmentation includes 100 mg (red or orange), 75 mg (orange) and 50 mg (yellow) tablets. These tablets are to be used once every five hours as needed to control pain. Additionally, tapentadol can be used for controlling the pain of diabetic neuropathy when around-the-clock analgesics are in demand.
However, tapentadol is known to have negative side-effects. It may weaken cognitive and physical abilities and should not be used when operating heavy machinery, especially during the initial treatment. Dizziness, constipation, nausea, and central nervous system sedation are common side-effects of tapentadol. Its consumption can raise the risk of seizure and should be administered to epileptic patients with extreme caution.
The growth in the demand for analgesics is projected to increase the demand for tapentadol. Moreover, the rising demand for OTC painkillers in the emerging economies of Asia Pacific is anticipated to boost product demand. The global market growth, however, is restricted by factors including s availability of substitutes, stringent government regulations, and negative effects of tapentadol.
North America is the leading tapentadol market in terms of revenue, followed by Europe and Asia Pacific. The demand for tapentadol is exceptionally high in the U.S., due to a higher population of the elderly population, a demographic which consists of the leading consumer pool for tapentadol. Asia Pacific is anticipated to be at the forefront of the global tapentadol market in terms of revenue growth. India and China are expected to show a very high rate of increase in the consumers of tapentadol due to their growing population pools and rapid urbanization rates. Expanding consumer awareness, advancement in treatment, and an increase in life expectancy will likely propel future market growth.
- The growing prevalence of chronic diseases is leading to the high occurrence of chronic musculoskeletal pain, which is likely to create an upward trend for the demand witnessed in the tapentadol market.
- Tapentadol is in the launch or post-launch phase in several countries across and awaiting to be commercially introduced in numerous countries.
- Its application segmentation includes 100 mg (red or orange), 75 mg (orange) and 50 mg (yellow) tablets.
- The rising demand for OTC painkillers in the emerging economies of Asia Pacific is anticipated to boost product demand.
The tapentadol market landscape is dominated by large pharma companies with established brands. Companies are investing in R&D to develop new grades of tapentadol. Additionally, companies are using acquisitions and mergers to remain competitive in the market and increasing their presence in emerging economies of Asia Pacific and Latin America. Some of the key players in the tapentadol market are Taj Pharmaceuticals Limited, Suzhou Shang Enda Biotechnology Ltd, Hangzhou Qichuang Chemical Co. Ltd, Shandong Chuangxin Pharmaceutical.
Segments Covered in the report
This report shows revenue growth at a global, regional & country level, and provides an analysis of the market trends in each of the sub-segments from 2022 to 2030. For this study, Reports and Data has segmented the tapentadol market based on type, application, and region
Type (Revenue in USD Million; Volume in Tons, 2022–2030)
- High Purity
- Low Purity
Application (Revenue in USD Million; Volume in Tons, 2022–2030)
- 50mg Tablet Product
- 75mg Tablet Product
- 100mg Tablet Product
Regional Outlook (Revenue in USD Million; Volume in Tons, 2022–2030)
- North America
- Rest of Europe
- Asia Pacific
- Rest of Asia Pacific
- South America
- Middle East & Africa
Buy quantitative research Report at discounted price – USD 1500 https://qyresearchmedical.com/report/checkout/119075/1500
You can place an order or ask any questions, please feel free to contact [email protected] | +1 9197 992 333
QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover North America, Europe, Latin America, Middle East and Africa, Asia- Pacific.
For Latest Update Follow Us:
URL – http://www.qyresearchmedical.com/